Soleno Therapeutics (SLNO) Research & Development (2013 - 2026)
Soleno Therapeutics (SLNO) posted quarterly Research & Development of $11.3 million for Q1 2026, down 16.59% year-over-year from $13.5 million in Q1 2025, and up 17.95% quarter-over-quarter from $9.6 million in Q4 2025.
Soleno Therapeutics (SLNO) Research & Development (2013 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Research & Development for 14 consecutive years, with $11.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 16.59% year-over-year to $11.3 million; the TTM figure through Mar 2026 stood at $38.4 million (down 50.46% YoY), while the FY2025 annual figure was $40.6 million, down 48.29% from the prior year.
- Research & Development advanced to $11.3 million in Q1 2026 per SLNO's latest filing, from $9.6 million in the prior quarter.
- Across five years, Research & Development topped out at $30.1 million in Q3 2024 and bottomed at $3.7 million in Q2 2022.
- Historically, Research & Development has averaged $10.1 million across 5 years, with a median of $8.7 million in 2023.
- Annual changes were most pronounced in 2024 — Research & Development jumped 398.73% — and 2025, when it tumbled 72.11%.
- Soleno Therapeutics' Research & Development stood at $3.8 million in 2022, then jumped by 128.06% to $8.7 million in 2023, then jumped by 147.28% to $21.5 million in 2024, then plunged by 55.52% to $9.6 million in 2025, then climbed by 17.95% to $11.3 million in 2026.
- Business Quant data shows SLNO's Research & Development at $11.3 million in Q1 2026, $9.6 million in Q4 2025, and $8.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn | 11.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.27 Mn |
| Dec 31, 2025 | 9.56 Mn |
| Sep 30, 2025 | 8.41 Mn |
| Jun 30, 2025 | 9.15 Mn |
| Mar 31, 2025 | 13.52 Mn |
| Dec 31, 2024 | 21.49 Mn |
| Sep 30, 2024 | 30.14 Mn |
| Jun 30, 2024 | 12.34 Mn |
| Mar 31, 2024 | 14.60 Mn |
| Dec 31, 2023 | 8.69 Mn |
| Sep 30, 2023 | 6.04 Mn |
| Jun 30, 2023 | 5.14 Mn |
| Mar 31, 2023 | 5.32 Mn |
| Dec 31, 2022 | 3.81 Mn |
| Sep 30, 2022 | 3.77 Mn |
| Jun 30, 2022 | 3.70 Mn |
| Mar 31, 2022 | 3.99 Mn |
| Dec 31, 2021 | 3.73 Mn |
| Sep 30, 2021 | 4.97 Mn |
| Jun 30, 2021 | 5.59 Mn |